At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Varenicline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lorcaserin for Preventing Weight Gain Among Smokers Receiving Varenicline: A Pilot Study
In Brief
A Phase 2 clinical trial evaluating Varenicline and Lorcaserin for Tobacco Use Disorder and Weight Gain. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This will be an open label clinical trial with all subjects receiving both lorcaserin and varenicline with a primary aim of reducing post cessation weight gain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder, Weight Gain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedMar 2015
Primary CompletionDec 2015
TodayJul 2026
First PostedMar 19, 2015
Enrollment StartSep 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.3 years ago
Interventions
Vareniclinedrug
All subjects receive Varenicline
Lorcaserindrug
All subjects receive Lorcaserin